ARS Pharmaceuticals Inc (NASDAQ:SPRY) has a beta value of 0.86 and has seen 1.02 million shares traded in the last trading session. The company, currently valued at $1.42B, closed the last trade at $14.00 per share which meant it gained $0.62 on the day or 4.63% during that session. The SPRY stock price is -32.21% off its 52-week high price of $18.51 and 66.79% above the 52-week low of $4.65. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.68 million shares traded. The 3-month trading volume is 1.08 million shares.
The consensus among analysts is that ARS Pharmaceuticals Inc (SPRY) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Sporting 4.63% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the SPRY stock price touched $14.00 or saw a rise of 2.57%. Year-to-date, ARS Pharmaceuticals Inc shares have moved 155.47%, while the 5-day performance has seen it change -0.07%. Over the past 30 days, the shares of ARS Pharmaceuticals Inc (NASDAQ:SPRY) have changed -9.09%. Short interest in the company has seen 12.6 million shares shorted with days to cover at 14.25.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 36.36% from current levels. The projected low price target is $18.0 while the price target rests at a high of $30.0. In that case, then, we find that the current price level is -114.29% off the targeted high while a plunge would see the stock gain -28.57% from current levels.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
Figures show that ARS Pharmaceuticals Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 55.90% over the past 6 months, with this year growth rate of 12.28%, compared to 16.70% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.44% over the past 5 years.
SPRY Dividends
ARS Pharmaceuticals Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
Insiders own 23.16% of the company shares, while shares held by institutions stand at 68.11% with a share float percentage of 88.64%. Investors are also buoyed by the number of investors in a company, with ARS Pharmaceuticals Inc having a total of 212.0 institutions that hold shares in the company. The top two institutional holders are DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) with over 11.08 million shares worth more than $94.27 million. As of 2024-06-30, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) held 11.4409% of shares outstanding.
The other major institutional holder is RA CAPITAL MANAGEMENT, L.P., with the holding of over 10.86 million shares as of 2024-06-30. The firm’s total holdings are worth over $92.43 million and represent 11.2168% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . As of Jun 30, 2024 , the former fund manager holds about 1.91% shares in the company for having 1.86 shares of worth $26.05 million while later fund manager owns 1.29 shares of worth $18.03 million as of Sep 30, 2024 , which makes it owner of about 1.33% of company’s outstanding stock.
